News

Zacks.com on MSN5d
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Zacks.com on MSN13d
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
Hosted on MSN2mon
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now? - MSN
As regards Pfizer, oncology sales ... of Pfizer’s diversified portfolio of drugs, particularly oncology, ... currently trade at 8.24 forward earnings, higher than 7.41 for Pfizer.
Nasdaq1mon
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Apart from oncology, Pfizer’s portfolio has a variety of drugs and vaccines for diseases like COVID-19, inflammation & immunology diseases, rare diseases and migraine, among others.
Nasdaq2mon
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
The continued growth of Pfizer’s diversified portfolio of drugs, particularly oncology, ... Merck’s shares currently trade at 8.24 forward earnings, higher than 7.41 for Pfizer.
Zacks Investment Research on MSN4d
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...